This publication evaluates the real-world use of non-invasive tests (LIVERFASt, FIB-4, and VCTE) in monitoring MASH patients undergoing resmetirom therapy. […]
This publication explores the relationship between psoriasis severity and liver steatosis using the AI-based LIVERFASt tool. Patients with more severe
Combining LIVERSTAT with Liver Stiffness Measurement (LSM) more effectively identifies advanced liver fibrosis (F3F4) in patients with MASLD, particularly those
Combining LIVERFASt with Liver Stiffness Measurement (LSM) is more effective than FIB-4 & LSM for identifying advanced liver fibrosis in
This publication introduces LIVERFASt, a non-invasive biomarker for predicting liver steatosis and fibrosis in patients with chronic Hepatitis B and
What Is Fatty Liver Disease? Fatty liver disease, now widely known as MASLD (Metabolic dysfunction-associated steatotic liver disease), is a
Fibronostics is pleased to announce its participation in the THASL 2025 Annual Conference, hosted by the Thai Association for the Study of the
Fibronostics is now officially SOC 2 Type II compliant! This compliance reflects our deep commitment to keeping your data and
When it comes to liver disease, early intervention isn’t just helpful, it’s critical. Known as the body’s “silent organ,” the
Inflammatory Bowel Disease (IBD), which includes Crohn’s disease and ulcerative colitis, is primarily known for affecting the gastrointestinal tract. However,